Acorda Therapeutics, Inc.
ACOR
Hisse Senetlerindeki Sıralama
#39149
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Hisse Fiyatı
$0.879
Son senkronizasyon: 2024-05-07
Piyasa Değeri
$582.38K
Değişim (1 gün)
9.88%
Değişim (1 yıl)
8,690.00%
Ülke
US
Ticaret Acorda Therapeutics, Inc. (ACOR)
Kategori
Healthcare
Acorda Therapeutics, Inc. (ACOR) için gelir
Mar 2024 itibarıyla gelir TTM: $115.66M
Acorda Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $115.66M'dir. 2022 yılında şirketin geliri $118.57M önceki yıla göre azalma 2021 yılındaki $129.07M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Acorda Therapeutics, Inc. için 2016 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $115.66M | -1.67% |
| 2023 | $117.63M | -0.79% |
| 2022 | $118.57M | -8.14% |
| 2021 | $129.07M | -15.62% |
| 2020 | $152.97M | -20.50% |
| 2019 | $192.41M | -59.19% |
| 2018 | $471.43M | -19.86% |
| 2017 | $588.29M | 13.22% |
| 2016 | $519.60M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 5,616.26% |
IN
|
